CEO Itescu needs to go, page-632

Thanks for your reply.

Go back to the feed back from the Covid Ards trial. FDA stoped clinical development for that indication. SI said at the time . This is not a hold on the IND. No but it was in reality.

The feed back from the FDA post CRL 1 was limited to the way forward rulling out further trials.

I think it safe to say that the IBD program is also on hold.

The data that I was refering to is all that has been released post CRL 1.

I note that you now think SI made a bad decision in regards to developing aGVHD. I am of the view that of all indications this is probabley the best to advance and it always has been.

The volume of data in the field is the primary reason, then you have the frount line telling us they see kids been cured. I remain very proud of our achivments.

Now to be critical of SI , I think to date mistakes have been made. The first big one was not to desighn 001 in a way that incorperated the work of the magic consortium. Bloods were been taken for reserch yet some how not all of 001 subjects had bloods taken on a regular time frame.